Asia Fresh News

Asia Fresh Stories

Archive for April 16th, 2015

Digital First Media, FAZ, Google, Schibsted and Nation join Publish Asia programme

leave a comment »

SINGAPORE, April 15, 2015 /PRNewswire/ — Publish Asia 2015, the annual Asian newspaper conference from the World Association of Newspapers and News Publishers (WAN-IFRA), is set to take place in Bangkok, Thailand from April 28-30.

With over 300 delegates, 40 speakers from 17 different countries, 19 conference sessions, 3 break-out sessions, several in-depth pre-conference masterclasses, a technology and services Expo featuring 21 sponsors and exhibitors and two glamorous evening networking events, Publish Asia 2015 will gather the Asian news media elite for three days of exciting learning and networking.

Registrations are open online for one more week at:

For its 16th edition, Publish Asia will focus on case studies showing how media companies across the globe are defining and implementing innovative strategies to consolidate their print operations while building up sound foundations to secure digital growth. Key sessions will cover the following topics:

Global Media Trends
Audience Development
The Resilience for Print
Diversifying Revenue Streams
From Newspaper to Broadcaster
Using Data & Analytics to Increase Profitability
Advertising Performances and Market Expectations
Safe journalists, Safe Sources
Content Discovery Optimization
Re-engineering Newsrooms for the Multimedia Era
Injecting Innovation into News Operations

Recently confirmed speakers at Publish Asia 2015 include:

Ludwig Coenen, Head of Online Marketing at Frankfurter Allgemeine Zeitung (FAZ), one of Germany’s most respected quality dailies. A Search Engine Optimization specialist with a track record for boosting online audiences, Coenen will explain at Publish Asia how FAZ has strengthened its online reach by building a separate content-index and by implementing dynamic widgets, automated recommendations and other innovative solutions.

Helje Solberg, CEO/Editor of VGTV, Schibsted’s web-native TV venture. VGTV is a next-generation business investment which aims at growing a substantial audience among video-centric, tablet and smartphone-using millenials.

Kirk MacDonald, President of AdTaxi and Executive Vice President of Sales for Digital First Media which jointly manages Journal Register Company and MediaNews Group with more than 800 print and online products serving 64 million Americans each month. At Publish Asia, MacDonald will share Digital First Media’s vision of the digital ecosystem and explain what are his company’s key orientations for growing its digital business.

Thepchai Yong, Group Editor-in-Chief of the Nation Multimedia Group, a multi-media company that operates 2 digital TV channels and 3 dailies. Yong is also the former director of the Thai Public Broadcasting Service. He will speak of the challenges for publishing companies to diversify in broadcasting.

Mark Pope, the Managing Director of Dow Jones Asia Pacific and Publisher of The Wall Street Journal Asia. He will share some of the WSJ’s current top business priorities and give some strategy insights for growing its business across Asian markets.

Dushyant Khare, Head of Google’s partnerships business with top digital & mobile publishers across SEA & India. The companies Khare partners with include news & broadcast media, telcos, ISPs, eCommerce and gaming organizations. He will speak at Publish Asia of new online business models, how to measure impact, and areas of cooperation for publishers and Internet companies.

Other confirmed speakers include:

Stephen Rae, Group Editor in Chief, Independent News & Media, Ireland
Maria Ressa, CEO and Executive Editor, Rappler, Philippines
Helena Phua, Executive Vice President – APAC, INYT, HK
Supakorn Vejjajiva, President & COO, Post Publishing, Thailand
Vachara Vacharaphol, CEO, VG3Trend, Thailand
JeongDo Hong, CEO, JMNet, South Korea
Mario Garcia, CEO, Garcia Media, USA
Pit Gottschalk, Managing Director, Axel Springer, Germany
Frederique Lancien, Digital and New Business Director, Groupe L’Equipe, France
Iain Martin, Asia Editor, Storyful, Hong Kong
Pichai Chuensuksawadi, Group Chief Editor, Post Publishing, Thailand
Abdul Jalil Hamid, Group Editor in Chief, NSTP, Malaysia
Keith Cheong, Head of Sales, SPH Digital, Singapore
Wannee Ruttanaphon, Chairman, IPG Mediabrands, Thailand
Nada Tielu, Head of Native, Fairfax Media, Australia
Yves Bougon, SVP MD, Asia, Hearst Magazines, Japan
Roche Chew, GM Agency Sales, NSTP, Malaysia
Andreas Vogiatzakis, CEO, OmnicomMediaGroup, Malaysia

The full conference programme is available at:


WAN-IFRA (, based in Paris, France, and Frankfurt, Germany, with subsidiaries in Singapore, India and Mexico is the world’s association of newspapers and news publishers. It represents more than 18,000 publications, 15,000 online sites and over 3,000 companies in more than 120 countries.

WAN-IFRA Asia Pacific office, based in Singapore, helps to bring services such as trainings, events, consulting and publications closer to members in the region.

Inquiries to:

Wilson Leong, Operations Manager, WAN-IFRA Asia Pacific Pte Ltd, Phone: +65.6562-8446, E-Mail:,,,

Logo –
Source: WAN-IFRA

Written by asiafreshnews

April 16, 2015 at 6:58 pm

Posted in Uncategorized

Menara Landmark Medical Suites Expands Healthcare and Medical Offerings in Johor Bahru

leave a comment »

JOHOR BAHRU, Malaysia, April 16, 2015 /PRNewswire/ — Private medical services have become an attractive alternative in Malaysia as the demand for faster, more customised medical care rises in tandem with affluence and heightened medical knowledge. This demand has given rise to the establishments of medical suites that deliver extensive range of medical and healthcare services promising more personalised attention and care. The latest of such development is Menara Landmark Medical Suites.

Strategically located in Iskandar Malaysia’s Flagship A of Johor Bahru City, Menara Landmark Medical Suites comprises four floors in Menara Landmark to provide a spectrum of medical services by highly specialised and well-known practitioners. This includes the Systemic Dialysis Centre led by Dr. Chin Chee Khin, and JB Oncology Centre, where its principal oncologist, Dr. A. Radzi, offers standard and complementary cancer treatment. Other services include Gribbles Pathology (M) Sdn. Bhd., TMC Fertility and Women’s Specialist Centre led by Dr. Fabian James Kurian, DMT Physio Sdn. Bhd., Bay Audiology (Malaysia) and well-renowned aesthetics and plastic surgery practice Beverly Wilshire Medical Centre (BWMC), led by Prof. Dato’ Dr. David Cheah Sin Hing. In addition to that, Clarity Radiology will also open its doors later this year.

Menara Landmark’s Managing Director of Business Development Mr. Tay Hui Fong says, “Our vision is to assemble like-minded medical professionals and create a symbiosis amongst practices. By doing that, we are providing convenience to patients who will benefit from having medical services in one location.”

Patients will definitely benefit from the collegiality amongst practitioners at Menara Landmark Medical Suites. Individual practices are able to collaborate, referring patients to practitioners and other medical service providers within the confines of Menara Landmark. Should a doctor require blood work, he merely has to consult Gribbles’ pathology laboratory. Practitioners have the option of conducting surgery within the building, thanks to BWMC’s state-of-the-art operating theatre manned by professional, dedicated and experienced personnel.

The building also has an ambulance parking bay, more than 600 parking spaces for patients and visitors, 24-hour security and a food court. It is also conveniently connected to DoubleTree by Hilton, giving patients and their family the option of recovery and rest in first-class accommodations.

Menara Landmark Medical Suites is not only giving Malaysians access to the country’s best medical minds, it will also accelerate medical-tourism to attract regional and international patients. After all, Malaysia has made a name for itself as “medical travel’s best-kept secret.” With an emphasis on high-quality medical infrastructure, facilities and multi-lingual personnel from diverse cultural backgrounds, Malaysia provides affordable medical care that rivals Japan, the United States and many countries in Europe.

Menara Landmark Medical Suites is also in line with Iskandar Malaysia’s Smart and Healthy Cities and Communities initiatives to ensure the economic region stays connected and with a higher quality of life through utilising and advancing technology.

Within driving distance of two airports — Senai International and Singapore’s Changi International just across the Causeway — Menara Landmark Medical Suites is a genuine medical tourism contender.

For more information on Menara Landmark Medical Suites, visit

Menara Landmark Medical Suites is owned by Daiman Properties Sdn. Bhd.

Source: Daiman Development Berhad

Written by asiafreshnews

April 16, 2015 at 6:31 pm

Posted in Uncategorized

FDA Advisory Committee Reviews Takeda’s Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial

leave a comment »

DEERFIELD, Illinois and OSAKA, Japan, April 15, 2015 /PRNewswire/ — Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that members of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States (U.S.) Food and Drug Administration (FDA) convened to review one of the first cardiovascular (CV) outcomes trials (CVOT) in patients with Type 2 diabetes, EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome). The Committee voted that, based on the data presented, the results of EXAMINE demonstrate that the use of alogliptin in patients with Type 2 diabetes has an acceptable CV risk profile. All 16 voting members of the Committee supported this recommendation. In addition, 13 out of 16 Committee members voted that safety information from the EXAMINE study should be added to the alogliptin labeling and the other three members voted for no change to the labeling.

“Patients with diabetes are at an increased risk of cardiac related comorbidities such as heart disease and stroke, as well as hospitalized heart failure and cardiac death,” said William B. White, MD, Professor, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, U.S., on behalf of the EXAMINE Steering Committee and Investigators. “Today’s Advisory Committee recommendation provides important information about alogliptin that may be useful for prescribing physicians as they consider appropriate treatment options for patients with Type 2 diabetes.”

EXAMINE, a large, randomized, double-blind, placebo-controlled outcomes study, was completed as a result of the U.S. FDA 2008 Guidance, titled “Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes,” for all Type 2 diabetes treatments under development since the issuance of the guidance. The EXAMINE trial was designed to evaluate CV safety following treatment with alogliptin in addition to standard of care, versus placebo in addition to standard of care, in patients with Type 2 diabetes who were at high risk for major adverse cardiovascular events (MACE) due to recent acute coronary syndrome (ACS). The trial’s primary objective was to evaluate non-inferiority of CV risk based on a primary composite endpoint of CV death, nonfatal myocardial infarction (MI) and nonfatal stroke.

“Takeda is pleased with the recommendation of the Committee and we remain confident in alogliptin as an important treatment option for patients living with Type 2 diabetes,” said Robert Jackson, MD, MBA, Vice President, Global Medical Head, CVM-Respiratory Therapy, Takeda Pharmaceuticals International. “Today’s outcome reinforces that the global EXAMINE trial met the FDA postmarketing guidance requirements. The trial is important as it assesses cardiovascular safety in patients known to be at a high risk for cardiovascular disease.”

Patient safety is a top priority for Takeda, and we remain committed to ongoing clinical research to understand and investigate potential safety concerns. Alogliptin has been studied as a monotherapy and in combination with metformin, a sulfonylurea (SU), a thiazolidinedione (TZD), and insulin in a comprehensive global clinical program comprising more than 50 clinical studies involving approximately 1,000 healthy adult patients and more than 17,000 adult patients with Type 2 diabetes.

The FDA also asked the Committee to discuss whether additional alogliptin studies are needed and to make any recommendations regarding the evaluation of the risk-benefit profile for alogliptin. In addition to discussing EXAMINE’s pre-specified primary CV outcome data, the Committee discussed other study analyses including heart failure, study data by geographic region, and other data including renal safety findings.

The outcome of the Advisory Committee meeting is non-binding and will be taken into consideration by the FDA.

Alogliptin is the first dipeptidyl peptidase-4 inhibitor (DPP-4i) to report out results on CV safety outcomes in Type 2 diabetes patients who are at high risk due to recent ACS. Heart disease, or cardiovascular disease (CVD), is a commonly occurring comorbid condition in patients living with Type 2 diabetes.

About the EXAMINE Trial

EXAMINE randomized 5,380 patients in 49 countries with Type 2 diabetes with an ACS within the previous 15-90 days. The EXAMINE primary endpoint of non-inferiority compared to placebo in addition to standard of care was met, showing no increase in CV risk in a Type 2 diabetes patient population at high risk for CV events based on the primary composite endpoint of CV death, nonfatal MI and nonfatal stroke. The primary endpoint occurred at similar rates in the alogliptin (n=305) and placebo (n=316) groups (in 11.3 percent of patients vs. 11.8 percent of patients during a median follow-up period of 18 months; hazard ratio (HR), 0.96; upper boundary of the one-sided repeated CI, 1.16).

About Alogliptin

Alogliptin is a DPP-4i for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise. DPP-4is are designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). As a result, an increased amount of active incretins enables the pancreas to secrete insulin in a glucose-dependent manner, thereby assisting in the management of blood glucose levels.

Alogliptin is approved as a monotherapy and also in fixed-dose combination (FDC) with pioglitazone and metformin HCl for the treatment of Type 2 diabetes in adults as adjuncts to diet and exercise. These therapies are not for treatment of Type 1 diabetes or diabetic ketoacidosis.

Takeda launched alogliptin in Japan in 2010. Since that time alogliptin has been launched in a variety of markets across the globe including the U.S. in 2013, as well as Italy, Austria, the United Kingdom, China, Mexico andSouth Korea. Diabetes prevalence continues to grow worldwide, with more than 382 million people impacted by diabetes. As the disease becomes increasingly prevalent, Takeda remains focused on expanding access of alogliptin, especially in emerging markets like Brazil, India and Russia.


NESINA is a DPP-4i for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise. DPP-4is slow the inactivation of incretin hormones GLP-1 and GIP. As a result, an increased amount of active incretins enables the pancreas to secrete insulin in a glucose-dependent manner, thereby assisting in the management of blood glucose levels.

KAZANO is an FDC therapy which combines alogliptin and metformin HCl in a single tablet for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise. Metformin HCl is a biguanide, a widely used anti-diabetes medication that acts primarily by reducing the amount of glucose produced by the liver.

OSENI is an FDC therapy which combines alogliptin and pioglitazone in a single tablet, for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise. Pioglitazone is a TZD that decreases insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels, and is approved in adults for the treatment of Type 2 diabetes as an adjunct to diet and exercise. An NDA for alogliptin and pioglitazone was approved in July 2011 by the Japanese Ministry of Health, Labour and Welfare for the treatment of Type 2 diabetes, and the therapy is currently available under the brand name LIOVEL in Japan.


Indications for NESINA (alogliptin) 6.25 mg, 12.5 mg, and 25 mg Tablets; KAZANO (alogliptin and metformin HCl) 12.5 mg/500 mg and 12.5 mg/1000 mg Tablets; and OSENI (alogliptin and pioglitazone) 25 mg/15 mg, 25 mg/30 mg, 25 mg/45 mg, 12.5 mg/15 mg, 12.5 mg/30 mg, and 12.5 mg/45 mg Tablets

NESINA, KAZANO, and OSENI are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.

NESINA, KAZANO, and OSENI are not for treatment of Type 1 diabetes or diabetic ketoacidosis.

Important Safety Information


Thiazolidinediones, including pioglitazone, which is a component of OSENI, cause or exacerbate congestive heart failure in some patients. After initiation of OSENI, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in OSENI must be considered. OSENI is not recommended in patients with symptomatic heart failure. Initiation of OSENI in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.


Lactic acidosis is a rare, but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure. The onset is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate. If acidosis is suspected, KAZANO should be discontinued and the patient hospitalized immediately.

NESINA, KAZANO, and OSENI are contraindicated in patients with a history of serious hypersensitivity reaction to any of the components of these products, such as anaphylaxis, angioedema, or severe cutaneous adverse reactions. KAZANO is contraindicated in patients with renal impairment (e.g., serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. KAZANO is contraindicated in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis. Do not initiate OSENI in patients with established NYHA Class III or IV heart failure.

Warnings and Precautions—for KAZANO

Lactic acidosis: Warn against excessive alcohol intake. KAZANO is not recommended in hepatic impairment and is contraindicated in renal impairment. Ensure normal renal function before initiating and at least annually thereafter. Temporarily discontinue in patients undergoing radiologic studies with intravascular iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Lactic acidosis due to metformin accumulation during therapy is fatal in approximately 50% of cases. The risk increases in patients with renal impairment, congestive heart failure requiring drug treatment, and with increasing age.

Vitamin B12 deficiency: Metformin may lower Vitamin B12 levels. Monitor hematologic parameters annually.

Warnings and Precautions—for OSENI

Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms.

Edema: Dose-related edema may occur. Use with caution in patients with edema.

Fractures: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health.

Bladder cancer: Data suggest an increased risk of bladder cancer in pioglitazone users. Data also suggest that the risk increases with duration of use. Do not use OSENI in patients with active bladder cancer. Use caution when using in patients with a prior history of bladder cancer. Tell patients to promptly report any sign of hematuria or other symptoms such as dysuria or urinary urgency as these may be due to bladder cancer.

Macular edema: Macular edema has been reported in some patients taking pioglitazone. Recommend regular eye exams. Instruct patients to report any visual changes promptly.

Ovulation: Therapy with pioglitazone may result in ovulation in some premenopausal anovulatory women.

Warnings and Precautions—for NESINA, KAZANO, and OSENI

Acute pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue NESINA, KAZANO, or OSENI.

Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions. In such cases, promptly discontinue NESINA, KAZANO, or OSENI, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema with another DPP-4i because it is unknown whether such patients will be predisposed to angioedema.

Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. Baseline liver test panel is recommended. If liver injury is detected, promptly interrupt NESINA, KAZANO, or OSENI and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart NESINA, KAZANO, or OSENI if liver injury is confirmed and no alternate etiology can be found. Use with caution in patients with hepatic impairment.

Hypoglycemia: Insulin and insulin secretagogues are known to cause hypoglycemia. A lower dose of the insulin or insulin secretagogue may be required to minimize the risk when used in combination with NESINA, KAZANO, or OSENI.

Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with NESINA, KAZANO, OSENI, or any other anti-diabetic drug.

Adverse Reactions

Most common adverse reactions (>4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) were nasopharyngitis (4.4%), headache (4.2%), and upper respiratory tract infection (4.2%).

Most common adverse reactions (≥4% of patients treated with co-administration of alogliptin and metformin) were upper respiratory tract infection (8%), nasopharyngitis (6.8%), diarrhea (5.5%), hypertension (5.5%), headache (5.3%), back pain (4.3%), and urinary tract infection (4.2%).

Most common adverse reactions (≥4% of patients treated with co-administration of alogliptin and pioglitazone) were nasopharyngitis (4.9%), back pain (4.2%), and upper respiratory tract infection (4.1%).

Drug Interactions

Use of OSENI with CYP2C8 strong inhibitors (e.g., gemfibrozil) will, or inducers (e.g., rifampin) may, require dose adjustment.

Cationic drugs eliminated by renal tubular secretion should be used with caution if taken with KAZANO.

Please see accompanying Full Prescribing Information, including Medication Guide, for NESINA.

Please see accompanying Full Prescribing Information, including Medication Guide, for KAZANO.

Please see accompanying Full Prescribing Information, including Medication Guide, for OSENI.

About Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc., located in Deerfield, Ill., is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. The company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervous system, general medicine, and vaccines. Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving towards better health for people worldwide through leading innovation in medicine. Through strategic acquisitions, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach. Additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website,

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

Additional information about Takeda is available through its corporate website,

Elissa J. Johnsen
Takeda Pharmaceuticals

Takeda Pharmaceutical Company Limited
Corporate Communications Dept.
Tel: +81-3-3278-2037

Written by asiafreshnews

April 16, 2015 at 5:28 pm

Posted in Uncategorized

Vienna: 2014 Second-Best Congress Year Ever

leave a comment »

Vienna reported its second-best congress result ever for 2014: compared to 2013, there were increases in events, as well as in the resulting overnights and value-added, the final result just falling short of 2012’s record.

VIENNA, April 15, 2015 /PRNewswire/ — “In 2014 Vienna achieved significant increases in all key congress indicators compared to the previous year,” reports Norbert Kettner, Director of the Vienna Tourist Board. “The number of conferences and corporate events rose by 6% to 3,582, a new record level. The resulting overnights were also up 6%, so the total of 1,490,695 was only slightly below the previous record in 2012. Austrian value-added induced by Vienna’s meetings industry increased 8% to 898.9 million euros, also the second-best figure after 2012.” In 2014 the Vienna conference industry therefore contributed 11% to Vienna’s total volume of overnights of 13.5 million. 17,000 year-round jobs were secured throughout Austria.

According to the statistics of the International Congress and Convention Association (ICCA), for years now Vienna has been one of the top three congress metropolises worldwide. “This success is attributable to many factors,” explains Kettner. “Meetings in the Austrian capital are optimally supported by urban and academic facilities, and with 36 licensed certification agencies for Green Meetings, Vienna has already demonstrated vision with respect to environmental sustainability. The city’s growing importance as a central European hub is also proving a valuable asset. New upmarket hotel accommodation and the creation of a new district around the Central Station have provided further impetus. Vienna currently has approximately 64,000 beds and is served by direct flights from about 170 destinations worldwide. The Vienna Tourism Strategy 2020 aims for another 20 direct connections from major cities worldwide – 72% of congress delegates arrive by plane.

Vienna Tourist Board
Isabella Rauter
Tel.: +43-1-211-14-301

Written by asiafreshnews

April 16, 2015 at 5:13 pm

Posted in Uncategorized

Asia Alternatives Announces Fund Closings of over US$1.8 billion

leave a comment »

HONG KONG, BEIJING, SHANGHAI and SAN FRANCISCO, April 15, 2015 /PRNewswire/ — Asia Alternatives, one of the largest independent Asian private equity fund-of-funds, today announced the final close of over US$1.8 billion in new commitments across Asia Alternatives Capital Partners IV, LP (“AACP IV”) and its related fund vehicles (“Fund IV”).

“We are extremely grateful that a significant number of our original limited partners continue to support us and we are pleased to have added a number of highly respected and well-recognized new investors in Fund IV,” said Melissa Ma, Co-Founder and Managing Director of Asia Alternatives.

The largest of the Funds is Asia Alternatives Capital Partners IV, LP which, along with its sleeve fund focused on investments outside Japan, AACP IV Ex-Japan Investors, LP, closed on US$1 billion of committed capital, above their combined target of US$750 million.AACP IV is the successor fund to Asia Alternatives Capital Partners III, LP (“AACP III”), which closed in July 2012. Earlier funds include Asia Alternatives Capital Partners II, LP (“AACP II”), which closed in September 2008, and Asia Alternatives Capital Partners, LP (“AACP I”), which closed in May 2007.

The Fund IV closings totaling over US$1.8 billion represent an approximate 20% increase over the last announced fund closings in August 2012 of over US$1.5 billion across AACP III and its related fund vehicles.

“In the 10th year since our founding, Asia Alternatives is proud of the strong partnerships we have formed with both our investors across the world and with our fund managers across China, India,Japan, Korea, South East Asia and Australia. The Asia private equity ecosystem has developed well over the last decade and we look to further growth for years to come,” Ma continued.

The Funds are focused on building a diversified portfolio with an emphasis on top-performing local Asian fund managers.  Asia Alternatives invests in Greater China, Japan, Korea, South East Asia, Indiaand Australia and across buyout, growth, venture capital and special situations funds.  The firm has invested in over 40 managers in Asia since inception.

“Portfolio construction is a critical focus at Asia Alternatives, as we seek risk diversification across geographies, strategies and managers that we actively monitor. The opportunity set for Asia private equity is continuously evolving and we intend to capitalize on those investments that provide the best risk-adjusted returns,” Ma concluded.

Approximately 80% of investors in AACP IV were from pre-existing relationships in AACP III, AACP II and AACP I. Investors in the Funds represent a global pool of private capital sources, such as state and corporate pension funds, foundations, university endowments, insurance companies and family offices in the United States, Canada, Europe and Asia.  Institutional investors across all Fund IV vehicles include Cathay Life Insurance Co., Comprehensive Financial Management, Florida State Board of Administration, Jasper Ridge Partners, Massachusetts Mutual Life Insurance Company, New York StateCommon Retirement Fund, San Francisco City and County Employees’ Retirement System, Teachers’ Retirement System of the State of Illinois, University of Missouri, University of Vermont and Virginia Retirement System.

Asia Alternatives is one of the first independently formed Asian private equity fund-of-funds.  The firm also received the first Limited Partner QFLP (Qualified Foreign Limited Partner) license in China, which allowed Asia Alternatives to invest in selected, qualified RMB-denominated private equity investments.

Eaton Partners, LLC acted as exclusive placement agent for Asia Alternatives and Pillsbury Winthrop Shaw Pittman LLP served as legal counsel.

About Asia Alternatives Management LLC
Asia Alternatives is a solution platform dedicated to helping institutional investors make investments in private equity across Asia.  The firm was founded in 2005 by Melissa Ma, Laure Wang and Rebecca Xu. Asia Alternatives is currently managing Asia Alternatives Capital Partners, LP ($515 million), Asia Alternatives Capital Partners II, LP ($950 million), Asia Alternatives Capital Partners III, LP ($908 million) and Asia Alternatives Capital Partners IV, LP and AACP IV Ex-Japan Investors, LP (collectively $1 billion) and other funds, all of which are Asia-focused private equity funds-of-funds.  The firm has over $6.5 billion in assets under management.

Asia Alternatives invests with top performing private equity fund managers across Asia primarily inGreater China (Mainland China, Taiwan, and Hong Kong), Japan, Korea, South East Asia, India andAustralia and that are diversified across buyout, growth and expansion, venture capital and special situations funds.  The firm currently has over 35 professionals across offices in Hong Kong, Beijing,Shanghai and San Francisco.  For more information, please visit

This press release does not constitute the offer of advisory services or offer of a security or the solicitation of an investment.

For More Information:

Investor Contact:
Melissa J. Ma – Co-Founder & Managing Director
Asia Alternatives Management LLC
Tel: +1 (415) 723-8101

Media Contact:
Steve Bruce/Taylor Ingraham/John Stavinga
ASC Advisors LLC
Tel: +1 (203) 992-1230

Media Contact for Asia Ex-Japan:
Richard Barton/Grace Zhang
Newgate Communications
Tel: (852)3758 2686 / (852)3758 2687

Media Contact for Japan:
Deborah Hayden/Ginger Lin
Tel: (813)4360 9000

Written by asiafreshnews

April 16, 2015 at 4:54 pm

Posted in Uncategorized

Avis Expands Operations in Taiwan with the Opening of 2 New Locations

leave a comment »

SINGAPORE and TAIPEI /PRNewswire/ — Avis Car Rental expands its footprint in Taiwan by launching operations at two new locations namely at 208, Banxin Road, Banqiao District, New Taipei City, which is minutes away from Banqiao Train Station and at No. 48, Zhongxing Road, West District, Chiayi City, close to the Taichung Railway Rear station. These new facilities are now open and ready to serve local city residents and travellers arriving by train.

Taiwan’s robust economy and leading position in financial and manufacturing has increased the demand for car rental and leasing services,” said Larry De Shon, president, International, Avis Budget Group. “We’re thrilled to deliver in line with our key strategic initiative and once again, expand our global footprint in this region.”

Both locations provide customers with wide variety of vehicles offering rent-a-car and leasing. Business and leisure travellers will benefit from quality, well-maintained vehicles from manufacturers such as Ford, Mercedes Benz and Nissan and services such as Global Positioning System (GPS) devices, child safety seats, vehicle damage coverage options and personal property protection packages.

For more information or to make a reservation, visit or call 1 800 600 601

About Avis in Taiwan

In 2012, Avis launches its Taiwan license operation. Avis Taiwan is the only international car rental company, as well as the only car rental which provides cross-border and cross-strait to Hong Kong and Macau.

Currently, Avis provides long-term lease, short-term rental and chauffeur drive promising efficient and convenient car rental service for travelers in Taiwan.

About Avis in Asia

In Asia, Avis is a leading provider of vehicle rental; vehicle leasing and limousine/chauffeur drive services operating in more than 300 locations through a network of wholly owned subsidiaries, joint ventures and licensee agreements in 20 markets. Avis opened its first operations in Asia in 1970 in Hong Kong. Throughout the 1970’s Avis grew steadily in the region, with operations launched in Singapore, the Philippines, Pakistan, Malaysia andIndonesia. More recently, developments have included openings in Vietnam, Taiwan, Laos and Cambodia.

About Avis

Avis Car Rental operates one of the world’s best-known car rental brands with approximately 5,750 locations in more than 165 countries. Avis has a long history of innovation in the car rental industry and is one of the world’s top brands for customer loyalty. Avis is owned by Avis Budget Group, Inc. (NASDAQ: CAR), which operates and licenses the brand throughout the world. For more information, visit

For further information please contact:
Grace Banto, Avis Asia (+65) 6737 1668

Source: Avis

Related stocks: NASDAQ-NMS:CAR

Written by asiafreshnews

April 16, 2015 at 4:54 pm

Posted in Uncategorized

New Geological Analysis Greatly Bolsters Probability Tomb of Jesus has Been Found

leave a comment »

— Geochemical comparison may prove “James ossuary” likely came from Israeli tomb containing cluster of New Testament names, according to Associated Producers
— Creators of controversial “Lost Tomb of Jesus” say study corroborates findings of the 2007 documentary

JERUSALEM, April 15, 2015 /PRNewswire/ — A recently completed study by an Israeli geologist has greatly increased the probability that an ancient tomb on the outskirts of Jerusalem is the final resting place of Jesus of Nazareth and his family.

The new findings by Dr. Aryeh Shimron have linked an ossuary, or bone box, inscribed with the phrase “James, son of Joseph, brother of Jesus” by its chemical “fingerprint” to a tomb encased in a rose garden between a group of nondescript apartments in Talpiot, a Jerusalem suburb. The tomb, discovered during construction in 1980, housed a remarkable collection of ossuaries upon which were inscribed several names associated with the family of the New Testament Jesus.

Although the names in the Talpiot Tomb, (which included “Jesus, son of Joseph,” “Maria,” “Mariamene,” “Yose,” and others) were common in first-century Jerusalem, a cluster of names associated with Jesus in one location is statistically compelling, and unique in the archeological evidence of his life. If yet another name associated with the New Testament family can now be sited at Talpiot, it becomes a kind of statistical snowball and creates a near-certainty that the tomb of Jesus of Nazareth has been found.

“I think I’ve got really powerful, virtually unequivocal evidence that the James ossuary spent most of its lifetime, or death time, in the Talpiot Tomb,” Shimron told the New York Times.

Dr. Shimron, a 25-year-veteran of the Israeli Geological Survey, believes that an earthquake in A.D. 363 flooded the Talpiot Tomb with a slurry of rendzina soil and mud that left the space “chemically frozen in time.” He says that the material embedded a unique geochemical “fingerprint” which, 1,652 years later, can be used for comparative analysis. Shimron tested roughly 100 samples of scrapings and soil from ossuaries, supplied to him by the Israeli Antiquities Authority, from 15 tombs throughout the Jerusalem area, including Talpiot. (In the first century, some affluent families stored the bones of departed family members in tombs carved out of the soft limestone that surrounds Jerusalem.)

Last month, Shimron was granted access to the James ossuary by owner Oded Golan and was finally able to conclude his seven-year study. His findings were remarkable: of the 100 samples, only the nine from the Talpiot Tomb and the James ossuary had matching geochemical profiles, which included magnesium, silicon and iron. A sample from a tomb just 60 meters away from the Talpiot Tomb had a markedly different profile.

Shimron’s findings provide a rigorous confirmation of a 2006 geochemical survey of ossuary patinas undertaken by journalist Simcha Jacobovici and noted filmmaker James Cameron and incorporated into the 2007 documentary “The Lost Tomb of Jesus,” which Cameron produced. Relying on the names inscribed on the ossuaries, along with supporting evidence from scholars and the Gospels themselves, the film concludes that the Talpiot Tomb, largely overlooked by Israeli officials, is the tomb of Jesus and his family.

Artifact collector Golan, igniting a debate over its origins and authenticity, first brought the James ossuary to public attention in 2002. In 2004, Golan was arrested and accused of forging the latter part of the inscription on the ossuary: “Brother of Jesus.” In 2012, after years of litigation, a Jerusalem district judge found Golan innocent and the ossuary was returned to him — this after Professor Wolfgang Krumbein, an international expert in ancient patina, testified that the entire inscription was authentic. Just how the James ossuary came into Golan’s possession remains unclear. If the Shimron study is correct, the ossuary was taken from the Talpiot Tomb at some point, either in recent history or antiquity, and ended up in Golan’s personal collection.

Experts say the cluster of New Testament names in the Talpiot Tomb is too remarkable to be a random occurrence or coincidence. In 2007, after extensive analysis of the occurrence of names in ancient Jerusalem, Andrey Feuerverger, professor of statistics at the University of Toronto, concluded that the odds of such a cluster of names—however common the individual names were—was highly unlikely unless they represented the family of Jesus of Nazareth. The film concludes that the odds of it not being the tomb of Jesus of Nazareth were only one in 600. Put another way, this is well over a 99% probability in favor of it being the tomb of the New Testament Jesus. The new forensic findings linking the James ossuary to the Talpiot Tomb now make the probability astronomical that it was, in fact, the tomb of the historical Jesus of Nazareth.

If Shimron has proven that the James ossuary came from the Talpiot Tomb, “the evidence can no longer be ignored,” argues Jacobovici. “The archaeology, the epigraphy, the statistics and, now, the hard chemical evidence all tell the same story. It’s arguably the most important archaeological find of all time.”

Contact: Nicole Austin, +1-416-504-6662

Source: Associated Producers

Source: Associated Producers
Related Links:

Written by asiafreshnews

April 16, 2015 at 4:40 pm

Posted in Uncategorized

CommunicAsia2015 will Uncover How the Surge in Mobile Usage is Transforming the Online Music Market in Asia

leave a comment »

-CommunicAsia2015 Summit speaker, Sunita Kaur, Managing Director, Asia, Spotify, shares how going mobile helped Spotify gain an edge and grow five times in Asia

SINGAPORE /PRNewswire/ — Picture this: you are going on a long trip and will be spending at least two hours on the road. You begin downloading songs onto your mobile device and then a pop-up appears. “Memory full. Please manage your storage in Settings.”

Online entertainment is moving from downloading to streaming on both PC and mobile devices for various reasons. The convenience and ability to cherry-pick your favourite content is already a good draw, but the true irresistible power of such streaming services comes from freeing up on storage space. You no longer have to pay for songs, instead you pay for access to a vast library of songs – a number much larger than a single device could conceivably store.

Mobile-only Asians

Not only does Asia have high mobile penetration rate, it is in fact, a growing mobile-only market. That is, mobile is the only connected device for many Asians, and the desktop experience is completely skipped. In Singapore for example, almost 70 percent of Spotify’s audience is between 18-34 years old, and over 70 percent are either a mobile-only or cross-platform user. With that, Spotify was launched in Asia with mobile as a priority, not as an afterthought or nice-to-have.

Since Spotify launched its mobile-free tier in the region in December 2013, mobile streams have gone up to as much as five times compared to the previous year. Looking at the numbers, the mobile-first strategy has also fuelled growth in Spotify’s user base, which subsequently bumped up premium subscriber numbers at an average conversion rate of about 20 per cent.

“We’re so committed to the freemium model on mobile because we completely agree with the labels that subscribers are key to bringing the industry back to health  and we need the free ‘funnel’ to drive subscription,” said Sunita Kaur, Managing Director, Asia, Spotify. “By bringing listeners into our free, ad-supported tier, we migrate them away from piracy, which is rife in this part of the world.”

For Spotify, the other obvious advantage of going mobile is the ability to provide personalised recommendations to music fans. “We are constantly charting and looking at usage data to provide users with a more comprehensive experience. We recommend music depending on what you are already listening to and curate playlists that fit every activity  whether you’re at a party, driving to work or studying, we have playlists that are with you at each moment. For example, we partnered with The Music Run™, and developed a digital tool that allows all music runners to listen, vote and share their favourite tracks,” added Kaur.

The result of tailoring the streaming experience to individual needs is that users are spending an average of over 160 minutes listening, dancing or singing along to Spotify every day.

Going Beyond the Play Button

Spotify believes that their best marketer has, and always will be, their users. By first considering the demands of the consumers, words about Spotify spread and profits eventually followed in the form of subscriptions and advertisements.

Elaborated Kaur, “Evidently, both our advertisers and 60 million active users are extremely important to the long-term survival of Spotify, and the music industry at large. We want to help brands connect to this engaged audience in a variety of ways, while ensuring that these advertisements will be more interesting and useful to consumers. Whether it’s advertising on our platforms or even co-creating campaigns that help brands tell their story through Spotify, we are the ultimate cross promotional tool.”

In the second quarter of this year, Spotify is announcing the roll out of a new video ad product. Sponsored Sessions give brands ownership of 30 minute ad-free mobile sessions. Users opt-in to an ad-free experience by viewing a 15 or 30 second video on their mobile device.

Kaur recalled what Daniel Ek, CEO and Founder of Spotify once said in an interview, “The reason I started Spotify was not because of my love of music. It was because I saw an opportunity to create something that made it easier for people to do the stuff that they were already doing, but legally.”

“That is precisely the advice I will give to any brands deliberating a mobile strategy. There is no cookie-cutter approach, so consider if your mobile strategy will add value to your consumers’ lifestyles. Learn to build for the user, go beyond mobile-first, and go user-first,” concluded Kaur.

For more insights on how businesses can implement a mobile marketing strategy, join Sunita Kaur, Managing Director of Asia, Spotify, at CommunicAsia2015 this June.

CommunicAsia2015 Summit


2-5 June 2015


Marina Bay Sands, Singapore, Level 3


Registered delegates only


CommunicAsia2015 / EnterpriseIT2015 Exhibition



Opening Hours:

2-4 June 2015: 10:30 am – 6:00 pm | 5 June 2015: 10:30 am –  4:00 pm


Business and trade professionals only

Website: |

About Spotify

Spotify is an award-winning digital music service that gives you on-demand access to over 30 million tracks. Our dream is to make all the world’s music available instantly to everyone, wherever and whenever you want it. Spotify makes it easier than ever to discover, manage and share music with your friends, while making sure that artists get a fair deal.

Spotify is now available in 58 markets globally with more than 60 million* active users, and over 15 million paying subscribers.

Since its launch in Sweden in 2008, Spotify has driven more than US$2bn to rights holders. Spotify is now the second biggest source of digital music revenue for labels in Europe, and the biggest and most successful music streaming service of its kind globally.

*Users active within the previous 30 days.

Further information

For more information, images, or to contact the team, please head over to our press page at

Media Enquiries:

June Seah / Patricia Yee

Singapore Exhibition Services

Tel: +65-6233-6621 / +65-6233-6637

Email: /

Anu Ramasamy / Fangying Ang

FleishmanHillard Singapore

Tel: +65-6424-6371 / +65-6424-6395

Email: /

Source: CommunicAsia2015

Written by asiafreshnews

April 16, 2015 at 3:32 pm

Posted in Uncategorized

A Pop Culture Icon, Refreshed: Consumers Around The World Take The #PepsiChallenge To Redesign The Iconic Pepsi® Can

leave a comment »

— #PepsiChallenge Global Ambassador Nicola Formichetti Unites Creative Leaders for Worldwide Design-Led Challenge
PURCHASE, New York, April 15, 2015 /PRNewswire/ — #PEPSICHALLENGE – Pepsi® is putting creative control of its most iconic brand equity, the Pepsi can, in the hands of fans. As part of the 2015 #PepsiChallenge, consumers will have the extraordinary opportunity to re-envision the universally celebrated and recognized can with their own special designs and creative flair in the “Live For Now” Design Challenge.

Photo –

Led by #PepsiChallenge global ambassador and world-renowned fashion designer and creative director, Nicola Formichetti, the “Live for Now” Design Challenge will kick-off with a design concept from Formichetti, featuring his beloved Nicopanda emblem, that will serve as inspiration and lay the groundwork showcasing where consumers can go with their own submissions. A blank Pepsi can, with only the logo intact, allows consumers to re-imagine the facade of the Pepsi can, with the only limitations their own imagination.

“I find inspiration around me constantly, particularly by the borderless world of design. From fashion and architecture to products and brands, design can be found in many mediums and created by individuals of all talents,” said Formichetti. “The ‘Live for Now’ Design Challenge was a challenge I couldn’t wait to accept and I am excited to see what the world conceives of and shares back.”

Beginning today and continuing through May 13th, submissions from around the world will be accepted on, with one (1) winning designer offered a once-of-a-lifetime design experience at the PepsiCo Design & Innovation Center in New York City working alongside PepsiCo’s industry-leading design team.

Top submissions will be judged by Formichetti, PepsiCo’s Senior Vice President and Chief Design Officer Mauro Porcini and a hand-selected committee of design-world notables, including:

Marcelo Burlon, Creative Director
Lapo Elkann, Chairman and Co-Founder of Italia Independent
Karim Rashid, Award-Winning Designer
Franca Sozzani, Editor-in-Chief of Vogue Italia

“The new Pepsi Challenge is all about encouraging consumers around the world to step out of their comfort zone and accept a new challenge and opportunity. Design has long been a haven for those who dare to do differently, so we wanted one of our first global challenges to connect with this bold creative class directly,” said Kristin Patrick, Senior Vice President and Chief Marketing Officer, PepsiCo Global Beverage Brands. “In a year of challenges, we have also turned the lens on ourselves to look at our brand differently. We’re turning over our most cherished piece of equity and our most visible piece of real estate – the facade of the Pepsi can – to consumers around the world to reimagine. We can’t wait to see the results.”

The “Live for Now” Design Challenge follows the Pepsi x Liter of Light “Ignite the Light” Tour where Formichetti challenged creative colleagues around the world to design art installations inspired by light. An international journey of creative, large-scale, mixed media art installations, the “Ignite the Light” Tour brings attention to communities that lack electricity and basic lighting solutions through the Pepsi global partnership with Liter of Light. Every time consumers around the world use the #PepsiChallenge hash tag on public Instagram, Facebook, Twitter or YouTube profiles, Pepsi will donate $1 to Liter of Light to help bring environmentally-friendly, inexpensive and easy to make lights to those around the world who need it most.

With a launch that marked #PepsiChallenge as the #1 Twitter trending topic worldwide, and engagements by and with Pepsi global brand ambassadors and international luminaries, fashion houses and sports celebrities alike, the Pepsi Challenge continues throughout 2015 with additional global and local challenges designed to galvanize consumers around the world to live life to the fullest and make every moment – big or small – epic. Challenges are issued on Pepsi social channels, and via global and local ambassadors. Visit and all Pepsi social channels around the world for more information and challenge details. Complete rules and eligibility requirements for the “Live for Now” Design Challenge are available on

About PepsiCo
PepsiCo products are enjoyed by consumers one billion times a day in more than 200 countries and territories around the world. PepsiCo generated more than $66 billion in net revenue in 2014, driven by a complementary food and beverage portfolio that includes Frito-Lay, Gatorade, Pepsi-Cola, Quaker and Tropicana. PepsiCo’s product portfolio includes a wide range of enjoyable foods and beverages, including 22 brands that generate more than $1 billion each in estimated annual retail sales. At the heart of PepsiCo is Performance with Purpose – our goal to deliver top-tier financial performance while creating sustainable growth and shareholder value. In practice, Performance with Purpose means providing a wide range of foods and beverages from treats to healthy eats; finding innovative ways to minimize our impact on the environment and reduce our operating costs; providing a safe and inclusive workplace for our employees globally; and respecting, supporting and investing in the local communities where we operate. For more information, visit

Source: PepsiCo

Written by asiafreshnews

April 16, 2015 at 3:23 pm

Posted in Food/Beverages

Aptuit LLC and Axxam SpA announce Strategic Alliance for Integrated Drug Discovery Services

leave a comment »

— Commence major integrated discovery program for large Pharma sponsor

GREENWICH, Connecticut and MILAN /PRNewswire/ — Aptuit LLC, a premier global drug discovery and development CRO and Axxam SpA, a leading discovery company with expertise in target biology and a broad range of early phase discovery solutions, announced a strategic alliance to provide comprehensive and integrated services from gene to high quality candidates and beyond. This partnership will allow the companies to offer the best-in-class fully integrated drug discovery and development services, supported by a culture of scientific excellence and innovation.

Jonathan Goldman, Chief Executive Officer, Aptuit LLC stated, “We serve biopharmaceutical companies in the discovery of small molecules in a broad range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. Our alliance  with Axxam is part of our growth strategy. This best-in-class partnership broadens Aptuit’s scientific excellence in advanced integrated discovery by leveraging Axxam’s capabilities in early discovery. In particular we are excited to enhance our hit identification, validation, and expansion services, by allowing seamless and very high quality delivery of an asset from target to candidate nomination.  Expected benefits include increased probability of successful IND candidate nomination, reduced timeline and reduced cost.”

Stefan Lohmer, co-founder and Chief Executive Officer of Axxam SpA, added, “We are very pleased to announce the strategic alliance with Aptuit. Our companies share a common culture of scientific excellence and quality. This alliance will allow some of our customers to leverage our deep expertise in target biology, assay development and High Throughput Screening even further.  This can be combined with downstream solutions at Aptuit towards candidate nomination and IND filing. The complementary and comprehensive skillsets of our two companies include all the scientific disciplines necessary to translate a promising target into a preclinical candidate. This alliance responds to the increasing demands from the market for high quality fully integrated drug discovery services.”

Aptuit and Axxam are also delighted to announce that the partnership has already resulted in the commencement of the first significant joint integrated project with a large pharma sponsor.

For more information about Aptuit please contact Nerina Coppini either by phone at +39 0458219248 or by email: For more information about Axxam, or to speak with Dr. Lohmer, please contact Sabrina Corazza at +39 02 2105634 or  

About Aptuit LLC (

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development center in Verona, Italy. The company maintains resources around the world, with facilities in the US, UK and Italy. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

About Axxam SpA (

Axxam SpA is a privately owned contract research and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.

Source: Aptuit LLC
Related Links:

Written by asiafreshnews

April 16, 2015 at 3:15 pm

Posted in Uncategorized